These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11561986)

  • 1. Adjuvant chemotherapy for muscle-invasive bladder cancer.
    Sun W; Vaughn DJ
    Semin Urol Oncol; 2001 Aug; 19(3):186-93. PubMed ID: 11561986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
    Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K
    Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer.
    Ohyama C; Hatakeyama S; Yoneyama T; Koie T
    Int J Urol; 2014 Jan; 21(1):3-4. PubMed ID: 24033445
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
    Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
    Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial.
    Crabb S; Danson SJ; Catto JWF; McDowell C; Lowder JN; Caddy J; Dunkley D; Rajaram J; Ellis D; Hill S; Hathorn D; Whitehead A; Kalevras M; Huddart R; Griffiths G
    Trials; 2018 Apr; 19(1):216. PubMed ID: 29615077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder.
    Dimopoulos MA; Moulopoulos LA
    J Clin Oncol; 1998 Apr; 16(4):1601-12. PubMed ID: 9552072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
    Froehner M; Koch R; Heberling U; Novotny V; Oehlschlaeger S; Hübler M; Baretton GB; Hakenberg OW; Wirth MP
    Eur Urol; 2016 Jun; 69(6):984-7. PubMed ID: 26194042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
    Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
    Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modern chemotherapy of invasive bladder cancer].
    Géczi L
    Magy Onkol; 2007; 51(2):133-8. PubMed ID: 17660869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.
    Yuh BE; Ruel N; Wilson TG; Vogelzang N; Pal SK
    J Urol; 2013 May; 189(5):1682-6. PubMed ID: 23123547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
    Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
    Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.
    Funt SA; Rosenberg JE
    Nat Rev Clin Oncol; 2017 Apr; 14(4):221-234. PubMed ID: 27874062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [When should systemic chemotherapy be used for urinary bladder carcinoma?].
    Ohlmann CH; Stöckle M
    Urologe A; 2012 Mar; 51(3):325-30. PubMed ID: 22012589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.
    Yang GL; Zhang LH; Liu Q; Wang ZL; Duan XH; Huang YR; Bo JJ
    Urol Oncol; 2017 Feb; 35(2):38.e9-38.e15. PubMed ID: 28040419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Krabbe LM; Westerman ME; Margulis V; Raj GV; Sagalowsky AI; Courtney K; Arriaga Y; Lotan Y
    Can J Urol; 2015 Aug; 22(4):7865-75. PubMed ID: 26267024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
    Kim PH; Kent M; Zhao P; Sfakianos JP; Bajorin DF; Bochner BH; Dalbagni G
    World J Urol; 2014 Apr; 32(2):453-9. PubMed ID: 23842986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
    Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
    Koie T; Ohyama C; Hashimoto Y; Hatakeyama S; Yamamoto H; Yoneyama T; Kamimura N
    Int J Clin Oncol; 2013 Aug; 18(4):724-30. PubMed ID: 23011100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.